Universal access to drug susceptibility testing for tuberculosis

This Lancet commentary makes a very compelling case for investing in DST for all patients with TB. levels of access to DST are nowhere close to sufficient. Under-investment in laboratory capacity in LMICs is a huge barrier and must be addressed for any meaningful progress.

Universal DST.pdf (131.9 KB)